CHANNEL 8 Ozempic Maker Novo Nordisk’s Investors Are Nervously Looking Into the Future
Mike Doustdar has spent the past year trying to convince Wall Street that Novo Nordisk’s best days are not behind it. The chief executive of the Danish pharmaceutical giant, best known for its blockbuster weight-loss and diabetes drug Ozempic, has been steering the company through a corporate turnaround that he insists is working, even as investors remain unconvinced.
The unease is not hard to understand. Novo Nordisk was, for a time, the most valuable company in Europe, riding a wave of enthusiasm over its GLP-1 drugs that transformed the obesity and diabetes treatment market almost overnight. But that enthusiasm has cooled considerably, as rivals crowd into the space and questions mount about how long Novo Nordisk can maintain its edge.
Doustdar argues that the market is missing the bigger picture. In his view, investors are too focused on near-term competitive threats and not focused enough on the long-term promise of the company’s drug pipeline and the sheer scale of demand for obesity treatments worldwide. He has framed his job as convincing skeptics that Novo Nordisk’s fundamentals remain sound, even if the stock has not behaved as though that were true.
A Turnaround Under Scrutiny
A year into his tenure, Doustdar has had to grapple with the reality that being the company that popularized Ozempic and Wegovy does not guarantee continued dominance. Competitors, most notably Eli Lilly, have pushed hard into the same market, offering their own versions of GLP-1 drugs and, in some cases, undercutting Novo Nordisk on price or convenience. That competitive pressure has weighed on investor sentiment, even as global demand for weight-loss drugs continues to grow.
The chief executive has had to balance defending the company’s existing products with reassuring shareholders that Novo Nordisk has more coming. He has pointed to the company’s pipeline of next-generation treatments as evidence that Novo Nordisk is not resting on the success of Ozempic and Wegovy alone, but is actively working to stay ahead of rivals racing to capture a share of what has become one of the most lucrative categories in modern pharmaceuticals.
Investors Wary Despite the Optimism
Still, the mood among investors reflects a broader wariness about betting on a single company to keep leading a market that has attracted intense global competition. Shares that once seemed to have nowhere to go but up have instead reflected the uncertainty now hanging over the sector. Doustdar’s challenge is to prove that Novo Nordisk’s advantages, its scientific expertise, its manufacturing scale, and its head start in the obesity drug race, are durable enough to fend off challengers.
“Investors are underestimating the promise of our drugs,” Doustdar has said, making clear that he believes the market has not fully priced in what he sees as the company’s long-term potential.
That promise, he argues, extends beyond the current generation of GLP-1 drugs into new formulations and delivery methods that could broaden the company’s reach even further. Whether that optimism translates into renewed investor confidence remains an open question, one that will likely take more than a year of turnaround efforts to answer definitively.
For now, Novo Nordisk finds itself in an unusual position for a company that helped create an entirely new pharmaceutical category: playing defense on its own turf, while trying to convince the market that its future is brighter than the recent stock performance would suggest. Doustdar’s bet is that patience, paired with continued innovation, will eventually win